ABSTRACT:A rapid and sensitive radiometric assay for assessing the potential of drugs to inhibit cytochrome P450 (P450) 3A4/5 in human liver microsomes is described. In contrast to the conventional testosterone 6-hydroxylation assay, the new method does not require high-performance liquid chromatography (HPLC) separation and mass spectrometry. The assay is based on the release of tritium as tritiated water that occurs upon CYP3A4/5-mediated 6-hydroxylation of testosterone labeled with tritium in the 6 position. The radiolabeled product is separated from the substrate using 96-well solid-phase extraction plates. The pharmacokinetic and toxicokinetic properties of pharmaceuticals depend in great part on their biotransformation by drug-metabolizing enzymes. The main drug-metabolizing system in mammals is cytochrome P450 (P450), a family of microsomal enzymes present predominantly in the liver. Multiple P450 enzymes catalyze the oxidation of chemicals of endogenous and exogenous origin, including drugs, steroids, prostanoids, eicosanoids, fatty acids, and environmental toxins (Ioannides, 1996). When a drug that is metabolized by a particular P450 enzyme is coadministered with an inhibitor of that same enzyme, changes in its pharmacokinetics can occur, which can give rise to adverse effects (Bertz and Granneman, 1997;Lin and Lu, 1998;Thummel and Wilkinson, 1998). It is therefore important to predict and prevent the occurrence of clearance changes due to metabolic inhibition. During the drug discovery process, it is routine practice in the pharmaceutical industry to assess the P450 inhibition potential of drug candidates to exclude potent inhibitors from further development (Lin and Lu, 1998;Crespi and Stresser, 2000;Riley, 2001). CYP3A4/5 is the most abundant P450 in human liver and is involved in the metabolism of about 50% of drugs used in human therapy (Guengerich, 1999). Inhibition of CYP3A4/5 activity can give rise to clinically significant and potentially life-threatening drug interactions (Thummel and Wilkinson, 1998). Several assay methods are currently used for determining the potential of drug candidates to inhibit CYP3A4/5 activity, and each of these methods presents distinct advantages and disadvantages. The most widely used method is the testosterone 6-hydroxylation assay, which is specific for enzymes of the CYP3A family (CYP3A4/5) (Waxman et al., 1988;Maenpaa et al., 1993;Wang et al., 1997;Yamazaki and Shimada, 1997). According to recent surveys conducted by reviewers in the Center for Drug Evaluation and Research of the United States Food and Drug Administration, the testosterone 6-hydroxylation assay represents the most commonly used probe reaction in support of new drug applications (Yuan et al., 1999(Yuan et al., , 2002. The practical challenge posed by this assay is that it requires HPLC separation of the reaction product from the substrate, followed by UV or mass spectrometric detection. This renders the assay relatively laborious, time-consumThis work was supported in part by a grant from t...